Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Griffith

Showing results (691-700 of 734) with videos related to

Pageof 74
Sort By:
Neurourology and Urodynamics|April 24, 2025
Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN II) Urinary Urgency Phenotyping Study: Methods and Baseline Urinary Symptoms by Age and SexGiulia M Ippolito, Kimberly Kenton, Catherine S Bradley, et al.
The Journal of Urology|May 7, 2018
Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary IncontinenceNazema Y Siddiqui, Jonathan B Wiseman, David Cella, et al.
Journal of Medicinal Chemistry|January 7, 2005
Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokineticsNatesan Murugesan, Zhengxiang Gu, Leena Fadnis, et al.
Journal of Medicinal Chemistry|December 28, 2002
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonistNatesan Murugesan, Zhengxiang Gu, Steven Spergel, et al.
The Journal of Urology|July 24, 2017
Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods StudyJames W Griffith, Emily E Messersmith, Brenda W Gillespie, et al.
The Journal of Urology|November 8, 2017
Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort StudyAnne P Cameron, Christina Lewicky-Gaupp, Abigail R Smith, et al.
Genes, Brain, and Behavior|August 13, 2009
Genetic architecture for hole-board behaviors across substantial time intervals in young, middle-aged and old miceJ E Foreman, A Lionikas, D H Lang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 2018
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory GuidanceSimone Schadt, Bojan Bister, Swapan K Chowdhury, et al.
Plos One|June 10, 2022
Subtyping of common complex diseases and disorders by integrating heterogeneous data. Identifying clusters among women with lower urinary tract symptoms in the LURN studyVictor P Andreev, Margaret E Helmuth, Gang Liu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 1, 2016
Biotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine δ-Oxidation and RearrangementWenying Li, Weiping Zhao, Xiaohong Liu, et al.
Pageof 74

Showing results (691-700 of 734) with videos related to

Sort By:
Pageof 74
Neurourology and Urodynamics|April 24, 2025
Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN II) Urinary Urgency Phenotyping Study: Methods and Baseline Urinary Symptoms by Age and SexGiulia M Ippolito, Kimberly Kenton, Catherine S Bradley, et al.
The Journal of Urology|May 7, 2018
Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary IncontinenceNazema Y Siddiqui, Jonathan B Wiseman, David Cella, et al.
Journal of Medicinal Chemistry|January 7, 2005
Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokineticsNatesan Murugesan, Zhengxiang Gu, Leena Fadnis, et al.
Journal of Medicinal Chemistry|December 28, 2002
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonistNatesan Murugesan, Zhengxiang Gu, Steven Spergel, et al.
The Journal of Urology|July 24, 2017
Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods StudyJames W Griffith, Emily E Messersmith, Brenda W Gillespie, et al.
The Journal of Urology|November 8, 2017
Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort StudyAnne P Cameron, Christina Lewicky-Gaupp, Abigail R Smith, et al.
Genes, Brain, and Behavior|August 13, 2009
Genetic architecture for hole-board behaviors across substantial time intervals in young, middle-aged and old miceJ E Foreman, A Lionikas, D H Lang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 2018
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory GuidanceSimone Schadt, Bojan Bister, Swapan K Chowdhury, et al.
Plos One|June 10, 2022
Subtyping of common complex diseases and disorders by integrating heterogeneous data. Identifying clusters among women with lower urinary tract symptoms in the LURN studyVictor P Andreev, Margaret E Helmuth, Gang Liu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 1, 2016
Biotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine δ-Oxidation and RearrangementWenying Li, Weiping Zhao, Xiaohong Liu, et al.
Pageof 74